
Tempus AI, Inc.
TEMNASDAQHealthcareMedical - Healthcare Information Services
前收盤價
US$72.69
+US$6.04 · +9.06%
TEM公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Hold
Wait — insufficient conviction to act
估值
72
Undervalued
動能
48
Neutral
情緒
47
Mixed
風險韌性
18
Extreme Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
- 產業
- Medical - Healthcare Information Services
- 部門
- Healthcare
- 總部
- US
- 執行長
- Eric Lefkofsky
- 上市以來
- 2024年6月14日
- 僱員
- 3,800
市場位置
日內區間
目前US$72.69,
52週區間
目前US$72.69,
- 開盤價
- US$65.74
- 前收盤價
- US$66.65
- 成交量
- 1597.31萬
- 2.46× 平均值
- 平均成交量
- 648.7萬
- 日均成交量
- 市值
- 127.35億 USD
- 貝塔
- 3.58
- 市場參考 1
- 50天平均值
- US$52.6604
- 高於平均水平+38.04%
- 200天平均值
- US$56.7758
- 高於平均水平+28.03%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 110.13億 USD
- 本益比(TTM)
- -50.83×
- 股價淨值比(TTM)
- 29.39×
- 股價營收比(TTM)
- 8.89×
- EV/EBITDA
- -92.93×
- 盈餘收益率
- -2.38%
- 自由現金流收益率
- -2.38%
- 股息率
- 0.00%
獲利能力和效率
- 毛利率
- 63.98%
- 營業利益率
- -19.76%
- 淨利潤率
- -17.77%
- 股東權益報酬率
- -49.87%
- 資產報酬率
- -10.77%
- 投入資本報酬率
- -10.90%
財務健康
- 負債權益比
- 3.25×
- 流動比率
- 3.13×
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 12.72億 USD | 6.93億 USD | 5.32億 USD | 3.21億 USD | 2.58億 USD |
| 銷貨成本 | 4.74億 USD | 3.12億 USD | 2.46億 USD | 1.9億 USD | 1.74億 USD |
| 毛利 | 7.98億 USD | 3.81億 USD | 2.86億 USD | 1.3億 USD | 8364.4萬 USD |
| 研究與開發 | 3.19億 USD | 3.17億 USD | 1.85億 USD | 1.62億 USD | 1.28億 USD |
| 銷售、一般及管理費用 | 7.15億 USD | 7.55億 USD | 2.97億 USD | 2.33億 USD | 1.99億 USD |
| 營業費用 | 10.51億 USD | 10.72億 USD | 4.82億 USD | 3.96億 USD | 3.27億 USD |
| 利息收入 | 1262.8萬 USD | 1108.4萬 USD | 760.1萬 USD | 303.2萬 USD | 62.3萬 USD |
| 利息支出 | 7026.7萬 USD | 5365.3萬 USD | 4686.9萬 USD | 2189.4萬 USD | 1518.4萬 USD |
| 折舊和攤銷 | 1.02億 USD | 3724.5萬 USD | 3333.2萬 USD | 3041萬 USD | 2388.1萬 USD |
| 營業利益 | −2.53億 USD | −6.91億 USD | −1.96億 USD | −2.65億 USD | −2.44億 USD |
| 淨利 | −2.45億 USD | −7.06億 USD | −2.14億 USD | −2.9億 USD | −2.59億 USD |
公司資料更新於 2026年8月24日。
分析師評級
第三方分析師預期可能變動,並非 GoAI 建議。
分析師目標價
平均目標
US$59.40
下跌空間 18.28%TEM同業公司
繼續GoAI的研究
在 GoAI 中研究TEMresearch.disclaimer





